Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. Regeneron on Tuesday said its board ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...

Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...